Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
POZEN reports revenue of $4.5 million for first quarter 2011

POZEN reports revenue of $4.5 million for first quarter 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene non-GAAP total revenue increases 40% to $1.11 billion

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Researchers create protein molecule for new anti-inflammatory therapies

Researchers create protein molecule for new anti-inflammatory therapies

The Arthritis Society awards $3.5 million grant for new research and training

The Arthritis Society awards $3.5 million grant for new research and training

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

VIMOVO granted marketing and pricing approval in the UK

VIMOVO granted marketing and pricing approval in the UK

SIMPONI injection improves inflammation, structural damage in RA patients

SIMPONI injection improves inflammation, structural damage in RA patients

Chronic lower back pain may be linked to axial spondyloarthritis: Research

Chronic lower back pain may be linked to axial spondyloarthritis: Research

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Study observes interaction between HLA-C and ERAP1 genes in psoriasis

Study observes interaction between HLA-C and ERAP1 genes in psoriasis

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.